TNF Pharmaceuticals, Inc. Common StockTNFA
About: TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms, Isomyosamine and Supera-CBD. Isomyosamine is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B. The company has one reportable segment focused on Isomyosamine.
Employees: 2
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
2.55% more ownership
Funds ownership: 4.6% [Q4 2024] → 7.15% (+2.55%) [Q1 2025]
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
4% less funds holding
Funds holding: 25 [Q4 2024] → 24 (-1) [Q1 2025]
53% less capital invested
Capital invested by funds: $146K [Q4 2024] → $69K (-$76.8K) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for TNFA.
Financial journalist opinion









